Table 2 Benchmark of Proposed Nodule Management Schedule against Existing Protocols
Recommendations | No. of participants (%, by column) | Lung Cancer diagnosed | Cancer-free | ||
|---|---|---|---|---|---|
within 3 mos (n = 31) | within 3–12 mos (n = 20) | after 12 mos (n = 10) | by study end (n = 31) | ||
AATS guideline, 2012 | |||||
 Diagnostic workup | 13 (14.1) | 3 (9.7) | 0 (0.0) | 1 (10.0) | 9 (29.0) |
 Follow-up in 3 mos | 2 (2.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (6.5) |
 Follow-up in 3–6 mos | 52 (56.5) | 21 (67.7) | 15 (75.0) | 4 (40.0) | 12 (38.7) |
 Follow-up in 6 mos | 25 (27.2) | 7 (22.6) | 5 (25.0) | 5 (50.0) | 8 (25.8) |
ACCP Guideline, 2013 | |||||
 Diagnostic workup | 1 (1.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (3.2) |
 Follow-up at 3 mos | 72 (78.2) | 23 (74.2) | 15 (75.0) | 8 (80.0) | 26 (83.9) |
 Follow-up in 6–12 mos | 2 (2.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (6.5) |
 Annual screen | 16 (17.4) | 8 (25.8) | 5 (25.0) | 1 (10.0) | 2 (6.5) |
 No further evaluation | 1 (1.1) | 0 (0.0) | 0 (0.0) | 1 (10.0) | 0 (0.0) |
 China Guideline, 2018 | |||||
 Follow-up after 1 mosa | 32 (34.8) | 15 (48.4) | 6 (30.0) | 0 (0.0) | 11 (35.5) |
 Follow-up after 3 mos | 56 (60.9) | 15 (48.4) | 13 (65.0) | 9 (90.0) | 19 (61.3) |
 Annual screen | 4 (4.3) | 1 (3.2) | 1 (5.0) | 1 (10.0) | 1 (3.2) |
Lung-RADS, 2019 or NCCN Guideline, 2020b | |||||
 Diagnostic workup | 42 (45.7) | 16 (51.6) | 7 (35.0) | 1 (10.0) | 18 (58.1) |
 Follow-up in 3 mos | 14 (15.2) | 0 (0.0) | 3 (15.0) | 2 (20.0) | 9 (29.0) |
 Follow-up in 6 mos | 18 (19.6) | 7 (22.6) | 5 (25.0) | 4 (40.0) | 2 (6.5) |
 Annual screen | 18 (19.6) | 8 (25.8) | 5 (25.0) | 3 (30.0) | 2 (6.5) |
Proposed radiomics approach | |||||
 Diagnostic workup | 26 (28.3) | 19 (61.3) | 6 (30.0) | 1 (10.0) | 0 (0.0) |
 Follow-up in 3 mos | 42 (45.7) | 11 (35.5) | 14 (70.0) | 9 (90.0) | 8 (25.8) |
 Annual screen | 24 (26.1) | 1 (3.2) | 0 (0.0) | 0 (0.0) | 23 (74.2) |